This page shows the latest talimogene laherparepvec news and features for those working in and with pharma, biotech and healthcare.
Phase III data for Amgen's cancer-killing virus product talimogene laherparepvec ( T-VEC) back what could be a potential advance in the treatment of melanoma.
The melanoma immunotherapeutic - talimogene laherparepvec ( also known as OncoVex) - works by introducing a virus that selectively replicates in tumour cells, causing them to rupture. ... All told, 16 per cent of patients treated with talimogene
The latest agreement with Amgen covers the use of MK-3475 alongside oncolytic immunotherapy talimogene laherparepvec in a phase Ib/II study in patients with previously untreated advanced melanoma.
Talimogene laherparepvec ( Onco-VEX GM-CSF, BioVex) is also undergoing phase III investigation for malignant melanoma in the US, UK, Canada and South Africa.